<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2014-4-ENG-34-38</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-604</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group></article-categories><title-group><article-title>КЛИНИЧЕСКИЙ АНАЛИЗ АССОЦИАЦИИ ЦИСТАТИНА С И ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ</article-title><trans-title-group xml:lang="en"><trans-title>CLINICAL ANALYSIS OF ASSOCIATION OF CYSTATIN C AND ATRIAL FIBRILLATION</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Liu</surname><given-names>Ping</given-names></name><name name-style="western" xml:lang="en"><surname>Liu</surname><given-names>Ping</given-names></name></name-alternatives><bio xml:lang="en"><p>MD, PhD, Department of Cardiology, the Second Hospital of Shandong University, No.247, Beiyuan Road, Jinan, Shandong 250033, P. R. China</p></bio><email xlink:type="simple">lping@sdu.edu.cn</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Sui</surname><given-names>Shujian</given-names></name><name name-style="western" xml:lang="en"><surname>Sui</surname><given-names>Shujian</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Xu</surname><given-names>Dongling</given-names></name><name name-style="western" xml:lang="en"><surname>Xu</surname><given-names>Dongling</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="en">The Second Hospital of Shandong University, Jinan, Shandong 250033, China</aff></aff-alternatives><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>28</day><month>04</month><year>2014</year></pub-date><volume>0</volume><issue>4-ENG</issue><fpage>34</fpage><lpage>38</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Liu P., Sui S., Xu D., 2014</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="ru">Liu P., Sui S., Xu D.</copyright-holder><copyright-holder xml:lang="en">Liu P., Sui S., Xu D.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/604">https://russjcardiol.elpub.ru/jour/article/view/604</self-uri><abstract><p>В некоторых исследованиях было выявлено, что фибрилляция предсердий (ФП) связана с воспалением. Цистатин С является не только воспалительным маркером, но и независимым предиктором сердечно-сосудистых событий.</p><sec><title>Цель</title><p>Цель. Мы попытались выяснить отношения между уровнем цистатина С в сыворотке крови и возникновением и развитием ФП.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. 134 пациента с пароксизмальной и персистирующей ФП (ФП1 группа), 121 пациент с постоянной ФП (ФП2 группа) и 154 здоровых людей в контрольной группе были под наблюдением для измерения цистатина С, других воспалительных маркеров, биохимических показателей, диаметра левого предсердия (LAD), диаметра левого желудочка (LVD) и фракции выброса левого желудочка (ФВ ЛЖ).</p></sec><sec><title>Результаты</title><p>Результаты. (1) В сравнении с группой контроля, группы ФП1 и ФП2 имели более высокие значения уровня цистатина С, высокую чувствительность C реактивного белка (hsCRP), LAD и LVDб в тоже время — низкие значения ФВ ЛЖ (P&lt;0,05). (2) После ранжирования по возрасту, полу и индексу массы тела (ИМТ), корреляционный анализ показал, что сывороточный уровень цистатина С тесно связан с hsCRP LAD, систолическим артериальным давлением (САД) и креатинином, коэффициенты корреляции были, соответственно, 0.658, 0.502, 0.475 и 0.530 (P&lt;0.01), но отрицательно ассоциированы с ФВ ЛЖ (Р=0,011) в группе с ФП. (3) Многофакторный регрессионный анализ показал, что hsCRP, цистатин С, LAD и ФВ ЛЖ в конечном счете входят в уравнение регрессии (цистатин С, OR: 3.41, 95%CI: 1.09–11.08, P=0.009).</p></sec><sec><title>Заключение</title><p>Заключение. Уровень цистатина С в сыворотке крови имеет значимые корреляции с ФП, которая указывает на то, что цистатин С, может играть важную роль в процессе развития ФП.</p></sec></abstract><trans-abstract xml:lang="en"><p>Some studies have disclosed atrial fibrillation (AF) is associated with inflammation. Cystatin C is not only inflammatory markers but also an independent predictor of cardiovascular events.</p><sec><title>Aim</title><p>Aim. We sought to investigate the relationship between serum levels of cystatin C and the occurrence and development of AF.</p></sec><sec><title>Material and methods</title><p>Material and methods. 134 paroxysmal and persistent AF (AF1 group) and 121 permanent AF (AF2 group) patients in AF group and 154 healthy people in control group were prospectively measured for cystatin C, other inflammatory markers, biochemical indicators, left atrial diameter (LAD), left ventricular diameter (LVD) and left ventricular ejection fraction (LVEF).</p></sec><sec><title>Results</title><p>Results. (1) Compared with control and AF1 groups, AF2 group had higher values of cystatin C, high sensitivity C reactive protein (hsCRP), LAD and LVD whereas lower values of LVEF (P&lt;0.05). (2) After adjust for age, gender and body mass index (BMI), correlation analysis showed that serum level of cystatin C was closely related to hsCRP, LAD, systolic blood pressure (SBP) and creatinine, the correlation coefficient were respectively 0.658, 0.502, 0.475 and 0.530 (P&lt;0.01), but negatively associated with LVEF (P=0.011) in AF group. (3) Multivariate regression analysis showed the hsCRP, cystatin C, LAD and LVEF entered finally into the regression equation (cystatin C, OR: 3.41, 95%CI: 1.09–11.08, P=0.009).</p></sec><sec><title>Conclusion</title><p>Conclusion. The serum levels of cystatin C has significant correlation with AF, which indicates cystatin C may play an important role in the process of AF development.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>цистатина С</kwd><kwd>фибрилляция предсердий</kwd><kwd>воспаление</kwd><kwd>маркеров воспаления.</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cystatin C</kwd><kwd>atrial fibrillation</kwd><kwd>inflammation</kwd><kwd>inflammatory markers</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ozaydin M. Atrial fibrillation and inflammation. World J Cardiol. 2010;2 (8): 243–50.</mixed-citation><mixed-citation xml:lang="en">Ozaydin M. Atrial fibrillation and inflammation. World J Cardiol. 2010;2 (8): 243–50.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Aldhoon B, Melenovský V, Peichl P, et al. New insights into mechanisms of atrial fibrillation. Physiol Res. 2010; 59 (1):1–12.</mixed-citation><mixed-citation xml:lang="en">Aldhoon B, Melenovský V, Peichl P, et al. New insights into mechanisms of atrial fibrillation. Physiol Res. 2010; 59 (1):1–12.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Conen D, Osswald S, Albert CM. Epidemiology of atrial fibrillation. Swiss Med Wkly. 2009; 139 (25–26):346–52.</mixed-citation><mixed-citation xml:lang="en">Conen D, Osswald S, Albert CM. Epidemiology of atrial fibrillation. Swiss Med Wkly. 2009; 139 (25–26):346–52.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hagiwara N. Inflammation and atrial fibrillation. Circ J. 2010;74 (2): 246–7.</mixed-citation><mixed-citation xml:lang="en">Hagiwara N. Inflammation and atrial fibrillation. Circ J. 2010;74 (2): 246–7.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012;60 (22):2263–70.</mixed-citation><mixed-citation xml:lang="en">Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012;60 (22):2263–70.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Smith JG, Newton-Cheh C, Almgren P, et al.Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol. 2010; 56 (21):1712–9.</mixed-citation><mixed-citation xml:lang="en">Smith JG, Newton-Cheh C, Almgren P, et al.Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol. 2010; 56 (21):1712–9.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lee SH, Park SA, Ko SH, et al. Insulin resistance and inflammation may have an additional role in the link between cystatin C and cardiovascular disease in type 2 diabetes mellitus patients. Metabolism. 2010;59 (2):241–6.</mixed-citation><mixed-citation xml:lang="en">Lee SH, Park SA, Ko SH, et al. Insulin resistance and inflammation may have an additional role in the link between cystatin C and cardiovascular disease in type 2 diabetes mellitus patients. Metabolism. 2010;59 (2):241–6.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Hadi HA, Alsheikh-Ali AA, Mahmeed WA, et al. Inflammatory cytokines and atrial fibrillation: current and prospective views. J Inflamm Res. 2010;3:75–97.</mixed-citation><mixed-citation xml:lang="en">Hadi HA, Alsheikh-Ali AA, Mahmeed WA, et al. Inflammatory cytokines and atrial fibrillation: current and prospective views. J Inflamm Res. 2010;3:75–97.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Battistoni A, Rubattu S, Volpe M. Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. Int J Cardiol. 2012;157 (2): 160–8.</mixed-citation><mixed-citation xml:lang="en">Battistoni A, Rubattu S, Volpe M. Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. Int J Cardiol. 2012;157 (2): 160–8.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Taglieri N, Fernandez-Berges DJ, Koenig W, et al. Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. Atherosclerosis. 2010;209 (1):300–5.</mixed-citation><mixed-citation xml:lang="en">Taglieri N, Fernandez-Berges DJ, Koenig W, et al. Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. Atherosclerosis. 2010;209 (1):300–5.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31 (19):2369–429.</mixed-citation><mixed-citation xml:lang="en">European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31 (19):2369–429.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Taglieri N, Koenig W, Kaski JC. Cystatin C and cardiovascular risk. Clin Chem. 2009; 55 (11): 1932–43.</mixed-citation><mixed-citation xml:lang="en">Taglieri N, Koenig W, Kaski JC. Cystatin C and cardiovascular risk. Clin Chem. 2009; 55 (11): 1932–43.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123 (25): 2946–53.</mixed-citation><mixed-citation xml:lang="en">Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123 (25): 2946–53.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">McManus DD, Corteville DC, Shlipak MG, et al. Relation of kidney function and albuminuria with atrial fibrillation (from the Heart and Soul Study). Am J Cardiol. 2009;104:1551–5.</mixed-citation><mixed-citation xml:lang="en">McManus DD, Corteville DC, Shlipak MG, et al. Relation of kidney function and albuminuria with atrial fibrillation (from the Heart and Soul Study). Am J Cardiol. 2009;104:1551–5.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Soliman EZ, Prineas RJ, Go AS, et al. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010;15 (6):1102–7.</mixed-citation><mixed-citation xml:lang="en">Soliman EZ, Prineas RJ, Go AS, et al. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010;15 (6):1102–7.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Targoński R, Salczyńska D, Sadowski J, et al. Relationship between inflammatory markers and clinical patterns of atrial fibrillation in patients with congestive heart failure. Kardiol Pol. 2008; 66 (7):729–36.</mixed-citation><mixed-citation xml:lang="en">Targoński R, Salczyńska D, Sadowski J, et al. Relationship between inflammatory markers and clinical patterns of atrial fibrillation in patients with congestive heart failure. Kardiol Pol. 2008; 66 (7):729–36.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Yap YG. Inflammation and atrial fibrillation: cause or para-phenomenon? Europace. 2009;11 (8): 980–1.</mixed-citation><mixed-citation xml:lang="en">Yap YG. Inflammation and atrial fibrillation: cause or para-phenomenon? Europace. 2009;11 (8): 980–1.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Conen D, Ridker PM, Everett BM, et al. A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. Eur Heart J. 2010;31 (14):1730–6.</mixed-citation><mixed-citation xml:lang="en">Conen D, Ridker PM, Everett BM, et al. A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. Eur Heart J. 2010;31 (14):1730–6.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Rienstra M, Sun JX, Magnani JW, et al. White blood cell count and risk of incident atrial fibrillation (from the Framingham Heart Study). Am J Cardiol. 2012;109 (4):533–7.</mixed-citation><mixed-citation xml:lang="en">Rienstra M, Sun JX, Magnani JW, et al. White blood cell count and risk of incident atrial fibrillation (from the Framingham Heart Study). Am J Cardiol. 2012;109 (4):533–7.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Qing X, Furong W, Yunxia L, et al. Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate. Cardiovasc Diabetol. 2012;11:108.</mixed-citation><mixed-citation xml:lang="en">Qing X, Furong W, Yunxia L, et al. Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate. Cardiovasc Diabetol. 2012;11:108.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Linssen GC, Rienstra M, Jaarsma T, et al. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail. 2011;13 (10):1111–20.</mixed-citation><mixed-citation xml:lang="en">Linssen GC, Rienstra M, Jaarsma T, et al. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail. 2011;13 (10):1111–20.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
